Double-blind trial of bestatin in HIV-positive patients.
Twenty-two HIV-positive homosexual men with a moderately impaired immune system were randomized to bestatin capsules 60 mg a day or placebo for 4 weeks. None suffered from opportunistic infections. The immunomodulating effect of bestatin was investigated by lymphocyte proliferation assay with pokeweed mitogen, phytohaemagglutinin, and concanavalin A, surface marker analysis of T-helper/T-suppressor cells by flow cytometry, natural killer cell activity, beta-2-microglobulin and HIV antibody quantitation. No significant differences between bestatin and placebo in immunological, haematological, biochemical or clinical variables were detected.
Hørding
M
M
Department of Infectious Diseases, Rigshospital, Copenhagen, Denmark.
Gøtzsche
P C
PC
Dalh Christensen
L
L
Bygbjerg
I C
IC
Faber
V
V
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000626:Aminopeptidases / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006679:HIV Seropositivity / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007930:Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male
D000276:Adjuvants, Immunologic; D000626:Aminopeptidases; D007930:Leucine; C012211:ubenimex